 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Former Traversa Exec Moves to Block Sale of Certain IP in Bankruptcy Proceedings
August 16, 2012
Former Traversa Exec Moves to Block Sale of Certain IP in Bankruptcy Proceedings
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - RNAi Drug Delivery Startup Solstice Closes $18M Series Financing Round
January 10, 2013 / Gene Silencing News - Bankrupt Traversa Settles IP Dispute as Alnylam, Isis Claim Delays in Tekmira Suit
September 6, 2012 / Gene Silencing News - Traversa Responds to Former Execs Bid to Block Sale of IP in Bankruptcy Proceedings
August 23, 2012 / Gene Silencing News - As Traversa Files for Bankruptcy, Co-Founder Seeks Partnership for Delivery Technology
May 31, 2012 / Gene Silencing News